SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

SCLP (SCLP) News

Follow SCLP (SCLP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol SCLP Asset market Sector Markets 90 days 4 Updated Sep 24, 2026, 05:03 AM UTC Open live news feed
L Scancell Holdings plc (SCLP) Secures Up To $25M Debt To Fund iSCIB1+ Phase 3 Scancell entered a loan agreement with BlackRock-managed funds for up to $25M, with $7M to be drawn after shareholder approval. Portions up to $5M are convertible; interest is 10.50%—10.95%, with warrants issued pro rata NEWS | Sep 24, 2026, 05:03 AM UTC L Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc AIM:SCLP (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherap NEWS | Sep 24, 2026, 05:02 AM UTC L Scancell to present at H.C. Wainwright global investment conference Sept 26 Scancell Holdings plc says it will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept 26. EQUITY | Sep 03, 2026, 01:00 PM UTC L Scancell to present at H.C. Wainwright 28th Annual Global Investment Conference Scancell Holdings plc announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference. EQUITY | Sep 03, 2026, 12:27 PM UTC